Sign in
CompletedPhase 3

Early Oseltamivir Carboxylate Low Plasma Concentration in Patients Admitted to Intensive Care for Severe Influenza.

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France23 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
155 people enrolled
Started
18 Dec 2023
Ended
12 Oct 2026
Type of study
Interventional
Record updated
3 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients over 18 years of age
  • Confirmed severe influenza infection requiring intensive care with tracheal intubation for invasive mechanical ventilation (influenza ARDS with or without bacterial co-infection, cardiorespiratory decompensation of influenza origin, influenza myocarditis)
  • Oseltamivir treatment administered through a gastric tube initiated since less than 24 hours (i.e. maximum two doses administered)
  • Affiliation to a social security scheme, beneficiary or beneficiary entitled (excluding AME)
  • Patient or, by default, a trusted support person or, by default, an informed family member who has given written consent or patient who has been included in emergency procedures

Who cannot take part

  • Previous treatment with Zanamivir or other antiviral treatment active against influenza virus for more than 24 hours
  • Administration of medication via nasogastric tube impossible
  • Current participation in a therapeutic interventional trial or be in the exclusion period at the end of a clinical trial (drugs that may interact with paracetamol or oseltamivir)
  • Co-infection with another respiratory virus (including SARS CoV-2)
  • Pregnant or breastfeeding woman
  • Patient deprived of liberty or under legal protection (guardianship or curatorship)
  • For patients not included in emergency situations: Inability, according to the investigator, to understand or refusal to sign the informed consent to participate in the study (non-French-speaking patient)
  • Weight less than 40 kg
  • Patient benefiting from AME (Aide Médicale d'Etat)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the prognostic impact of early plasma underdosing (measured at 48 hours of treatment) of oseltamivir carboxylate (OC) on early morbidity and mortality in patients hospitalized in the ICU for severe influenza infection.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
OPTIFLU. Prognostic Impact of Early Oseltamivir Carboxylate Low Plasma Concentration in Critically Ill Patients With Severe Influenza: a Prospective Cohort Study
Record updated
3 February 2026